Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update.
Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, Sato S, Nishida Y, Nozawa T, Yamasaki Y, Yamazaki K, Arai S, Nishino I, Mori M. Kobayashi I, et al. Among authors: yamazaki k. Mod Rheumatol. 2020 May;30(3):411-423. doi: 10.1080/14397595.2020.1718866. Epub 2020 Feb 3. Mod Rheumatol. 2020. PMID: 31955618 Review.
Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".
Yokota S, Kikuchi M, Nozawa T, Kanetaka T, Sato T, Yamazaki K, Sakurai N, Hara R, Mori M. Yokota S, et al. Among authors: yamazaki k. Mod Rheumatol. 2015 Jan;25(1):1-10. doi: 10.3109/14397595.2014.902747. Epub 2014 May 20. Mod Rheumatol. 2015. PMID: 24842480 Review.
Validation of Classification Criteria of Macrophage Activation Syndrome in Japanese Patients With Systemic Juvenile Idiopathic Arthritis.
Shimizu M, Mizuta M, Yasumi T, Iwata N, Okura Y, Kinjo N, Umebayashi H, Kubota T, Nakagishi Y, Nishimura K, Yashiro M, Yasumura J, Yamazaki K, Wakiguchi H, Okamoto N, Mori M. Shimizu M, et al. Among authors: yamazaki k. Arthritis Care Res (Hoboken). 2018 Sep;70(9):1412-1415. doi: 10.1002/acr.23482. Epub 2018 Jul 5. Arthritis Care Res (Hoboken). 2018. PMID: 29195002
Infliximab for the Treatment of Refractory Kawasaki Disease: A Nationwide Survey in Japan.
Masuda H, Kobayashi T, Hachiya A, Nakashima Y, Shimizu H, Nozawa T, Ogihara Y, Ito S, Takatsuki S, Katsumata N, Suzuki Y, Takenaka S, Hirono K, Kobayashi T, Suzuki H, Suganuma E, Takahashi K, Saji T; Committee of Survey on Infliximab use for Kawasaki disease. Masuda H, et al. J Pediatr. 2018 Apr;195:115-120.e3. doi: 10.1016/j.jpeds.2017.10.013. Epub 2017 Dec 7. J Pediatr. 2018. PMID: 29224935
External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort.
Yamazaki K, Ohta A, Akioka S, Yamasaki Y, Ohara A, Nakaseko H, Nishimura K, Kobayashi N, Nishida Y, Sato S, Takezaki S, Kishi T, Hashimoto M, Kobayashi I, Mori M; group of Juvenile Idiopathic Inflammatory Myopathies in the Research Team for Pediatric Rheumatic Disease, The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare. Yamazaki K, et al. Rheumatology (Oxford). 2021 Feb 1;60(2):802-808. doi: 10.1093/rheumatology/keaa274. Rheumatology (Oxford). 2021. PMID: 32810274
Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
Yamasaki Y, Kobayashi N, Akioka S, Yamazaki K, Takezaki S, Nakaseko H, Ohara A, Nishimura K, Nishida Y, Sato S, Kishi T, Hashimoto M, Mori M, Okazaki Y, Kuwana M, Ohta A. Yamasaki Y, et al. Among authors: yamazaki k. Rheumatology (Oxford). 2021 Oct 2;60(10):4821-4831. doi: 10.1093/rheumatology/keab108. Rheumatology (Oxford). 2021. PMID: 33576399
3,348 results